OBJECTIVE: Postpartum hemorrhage (PPH) is a leading cause of mortality and severe maternal morbidity (SMM). Research evidence demonstrates increasing risk for PPH, PPH severity, and associated morbidity. In response, the New York State Safe Motherhood Initiative (SMI) supported implementation of a bundle to improve management of PPH. We sought to assess (i) trends in PPH utilizing a novel multi-severity-level framework and (ii) hemorrhage-associated morbidity during PPH bundle implementation. STUDY DESIGN: This study analyzed PPH at a large, multi-site academic medical center from 7/2014 to 7/ 2017 during SMI hemorrhage bundle implementation. A novel framework was developed to track PPH risk factors, PPH severity, and indicators of PPH undertreatment. We analyzed changes in PPH levels over time using logistic regression accounting for PPH risk factors. Low fibrinogen levels were analyzed as a proxy for coagulopathy as an indicator for under-treatment. For these analyses, patients with no PPH were compared to patients with PPH based on severity within our framework.
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RESULTS:
Using a framework of PPH that includes 4 severity levels ( Figure 1A ), we found variation across time in incidence of PPH and treatment patterns ( Figure 1B ). PPH did not change over time according to ICD coding ("Coded PPH" in Figure 2A ). However, usage of uterotonics other than Pitocin increased significantly ("PPH1" in Figure 2A ), as did usage of Bakri Balloons and small volume (1-3 unit) red blood cell (RBC) transfusions ("PPH3" in Figure 2A ). Hysterectomy and/or RBC transfusion 4 units did not increase significantly ("PPH4" in Figure 2A ). Cases with fibrinogen<¼200, an under-treatment indicator, did not increase significantly over time (p¼0.10 in logistic regression) and there were no PPH related maternal mortalities during hospitalization in the study period. CONCLUSION: Based on trends in uterotonic use, transfusion <4 units RBCs and Bakri use, PPH incidence and risk appeared to increase. This risk was not captured in routine billing data. Hemorrhage bundles call for early recognition of PPH with stagebased response including uterotonic medication, tamponade, and transfusion. Clinical uptake of these recommendations occurred over the study period. Despite increases in PPH risk and severity, key measures of SMM, including hysterectomy and coagulopathy, did not increase.
Poster Session I OBJECTIVE: While the 50% increase in primary cesarean rates since 2000 was not clearly associated with improved neonatal outcomes, it is unknown how a large-scale program to actively support vaginal birth and reduce primary cesarean rates will affect neonatal and maternal outcomes. STUDY DESIGN: A California multi-disciplinary quality collaborative beginning in mid 2016 focused on hospitals with high rates of cesarean delivery among nulliparous women whose pregnancies were at term, singleton, and vertex (NTSV). The collaborative focused on implementation of ACOG/SMFM guidelines for labor management and increasing nursing labor support. Operative vaginal deliveries were not emphasized. Inclusion criteria for analysis included a minimum of 200 annual NTSV births and a 2015 NTSV rate >23.9%. Monthly neonatal and maternal outcome measures were collected as part of a safety monitoring program. Data were collected for the baseline period (2015) and the intervention years (2016) (2017) . The primary neonatal measure was the NQF composite outcome metric: Severe Unexpected Newborn Complications (sUNC) which includes hypoxic ischemic encephalopathy, ventilation, neonatal sepsis, and major birth injuries. RESULTS: 46 hospitals met inclusion criteria with a mix of hospital types: university, community, and integrated health system; and high, medium and small delivery volume. They included an annual average of 115,000 births (of which 35% were NTSV). Overall NTSV Cesarean rates declined by 4.2%points or -14.3%. Rates of sUNC, 5' Apgar <5, and 3 rd /4 th degree perineal lacerations did not change throughout the collaborative (Figure) . Hospital NTSV cesarean rate declines occurred over a broad range from -16.7 %points to +4.7 % points, therefore, we separated the hospitals into terciles based on degree of reduction. Hospitals with the greatest declines in NTSV cesarean rate (average -9.7 % points or -29.5%) also had no change in their sUNC, low Apgar or laceration rates (Table) . Rates of chorioamnionitis, transfusion, and operative vaginal delivery also did not change. CONCLUSION: Mothers and neonates participating in a large-scale Supporting Vaginal Birth Collaborative had no evidence of worsened birth outcomes even in hospitals with very large NTSV cesarean
